<DOC>
	<DOCNO>NCT02243891</DOCNO>
	<brief_summary>The study test hypothesis ablation paroxysmal atrial fibrillation hypertensive subject effective ROX coupler insert concurrently .</brief_summary>
	<brief_title>AF Ablation With Without ROX Coupler Study</brief_title>
	<detailed_description>The single blind , randomise study plan commence October 2014 obtain Research Ethics Committee NHS Research Development approval . A target 20 participant symptomatic paroxysmal AF recruit . All participant blind randomised AF ablation AF ablation + ROX coupler implant . All participant right leave heart catheterisation prior AF ablation +/- ROX coupler insertion . Participants follow 6 week , 3 , 6 month 12 month ablation . The study take place Eastbourne District General . The study duration per patient 13months . The overall study duration 18 month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Symptomatic paroxysmal AF suitable AF ablation . Office Systolic blood pressure ≥ 140 mmHg base average 3 blood pressure reading Ambulatory Blood Pressure Monitoring ( ABPM ) daytime average systolic blood pressure ( SBP ) ≥ 135 mmHg ; Resistant Hypertension : Patients establish hypertension ( diagnose ≥ 12 month prior baseline ) guideline base drug regimen stable fully tolerate dose , consist ≥3 hypertensive medication ( include 1 diuretic ) , Uncontrolled Hypertension : Patient drug intolerance antihypertensive medication unable take guideline base drug regimen VO2 peak &gt; 15mls/Kg/min Cardiopulmonary exercise testing ( CPX ) Peak RER &gt; 1.0 Cardiopulmonary exercise test Age 18 year old . Informed consent participate study . Secondary hypertension amenable conventional therapy Left ventricular systolic dysfunction EF &lt; 50 % E/E ' &gt; 15 transthoracic echocardiography Uncontrolled diabetes . Body Mass Index &gt; 40 kg/m2 Contraindicated treatment arteriovenous anastomosis interventional vascular procedure Severe chronic kidney disease indicate estimate glomerular filtration rate &lt; 30 mL/min/1.73m2 use MDRD calculation Renal denervation within last 6 month Significant peripheral arterial and/or venous disease lower limb ( include unprovoked deep vein thrombosis , significant low extremity edema and/or venous insufficiency ) Current diagnosis unstable cardiac disease require intervention , significant history serious cardiac comorbidity may affect patient safety study outcomes Current diagnosis severe cerebrovascular disease stroke within past year Female patient pregnant , breastfeed plan become pregnant ; female childbearing potential must negative urine pregnancy test prior treatment Any known , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , would unlikely unable comply study followup requirement Scheduled plan surgery next 6 month may affect patient safety study outcomes Concurrent enrollment another clinical trial without prior approval ROX Medical , Inc. Any serious medical condition may adversely affect patient 's safety , limit subject 's ability participate study , comply followup requirement impact scientific integrity study Intolerant allergic antithrombolytic medication include aspirin Pulmonary arterial hypertension ( PAH ) define mean pulmonary artery pressure ( mPAP ) &gt; 30 mmHg measure right heart catheterization Pulmonary capillary wedge pressure ( PCWP ) &gt; 15mmHg measure right heart catheterization Preexisting ILRs permanent pacemaker allow continuous monitoring AF occurrence . Participation conflict study . Potential participant mentally incapacitated consent comply followup . Pregnancy . Other cardiac rhythm disorder . Severe aortic mitral valve disease . Previous ROX coupler implantation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>